331742
Determination of Benchmark Risk of Colorectal Cancer (CRC) at Subsequent Surveillance Colonoscopies
Methods: A population-based, retrospective cohort study was identified in a database of colonoscopy screening and surveillance. Patients had colonoscopy (January 2010- March 2014) were selected as study subjects and their examination history was reviewed. Multivariable Weibull regression model was used to estimate the incidence of CRC at 10-year follow-up among patients with low risk level (neither CRC history nor polyp), which was defined as the benchmark risk because the national guidelines recommend a 10-year surveillance interval for them. Results:
Results: Out of total 27,325 events, 5774 (21%) didn’t find any polyp at baseline colonoscopies. Half of them were male, average age was 61±9 years. The incidence at 10-year follow-up (benchmark risk) was 164 and 79 per 100,000 person-years for male and female, respectively. Both male and female exceeded their benchmarks in 3-5 years if they had incomplete polyp removal, ≥3 adenomas during last colonoscopy or personal CRC history, while in 5-10 years if only family CRC history was present. Coexisting risk factors resulted in a sharp increase in the incidence exceeding the benchmarks in less than 2-3 years Conclusions:
Conclusions: The benchmark risk of CRC at subsequent colonoscopy could be used as a threshold for examining surveillance intervals. Gender disparity and coexisting risk should be considered in the future adjustment of intervals.
Learning Areas:
Biostatistics, economicsClinical medicine applied in public health
Epidemiology
Implementation of health education strategies, interventions and programs
Social and behavioral sciences
Learning Objectives:
Identify the benchmark risk of colorectal cancer at subsequent surveillance colonoscopies
Keyword(s): Cancer Prevention and Screening, Epidemiology
Qualified on the content I am responsible for because: I have been the co-investigator of multiple federally funded grants focusing on the epidemiology of obesity and breast cancer.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.